Yale University

Icahn School of Medicine at Mount Sinai

National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States Government As Represented by the Department of Veterans Affairs

National Institute of Health

John H Krystal

Gerard Sanacora

Dennis S Charney

Vladimir Coric

Carlos A Zarate

Husseini K Manji

Sanjay J Mathew

Chadi Abdallah

Ronald Duman

John P Seibyl

Vladmir Coric

The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.

Combination therapy for treating or preventing depression or other mood diseases

Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.

Glutamate agents in the treatment of mental disorders

Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (&#x3e;2 years).

Intranasal administration of ketamine to treat depression

Methods for treating suicidal ideation

Mazindol and other dopamine and/or noradrenergic reuptake inhibitors are effective to treat negative symptoms in schizophrenia.

Dopamine and noradrenergic reuptake inhibitors in treatment of

Growing community of inventors

Woodbridge, CT, United States of America

John H Krystal